Deutsche Bank
IKT icon

Deutsche Bank’s Inhibikase Therapeutics IKT Stock Holding History

Deutsche Bank’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206K Buy
122,442
+67,533
+123% +$120K ﹤0.01% 2995
2025
Q4 		$113K Sell
54,909
-25,587
-32% -$40.7K ﹤0.01% 3258
2025
Q3 		$130K Buy
+80,496
New +$139K ﹤0.01% 3253

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deutsche Bank's IKT Position: Q1 2026 in Review

Deutsche Bank increased its Inhibikase Therapeutics (IKT) stake by 123% in Q1 2026, buying an estimated $120K and bringing the position to 122,442 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #2995.

Deutsche Bank first reported a position in IKT in Q3 2025 and has held it in 3 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Deutsche Bank held 122,442 shares of Inhibikase Therapeutics worth $206K as of Q1 2026.
  • Deutsche Bank bought 67,533 Inhibikase Therapeutics shares in Q1 2026, an estimated $120K.
  • Inhibikase Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #2995 holding.
  • Deutsche Bank first reported a position in Inhibikase Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.